SEOUL: Samsung Biologics Co Ltd, the biopharmaceutical contract manufacturing affiliate of Samsung Group, said on Thursday that it decided to pursue an initial public offering in South Korea in 2016.
The company said in a statement that it will pick advisors for the IPO in May.
Analysts have estimated the company's market capitalization to be around 10 trillion won ($8.72 billion) or more.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
